12 Month Price Forecast For IBIO
Distance to IBIO Price Forecasts
IBIO Price Momentum
๐ค Considering iBio (IBIO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 4:09 PM UTC
IBIO Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, IBIO has a bullish consensus with a median price target of $4.78 (ranging from $3.60 to $5.96). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $3.43, the median forecast implies a 39.4% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Kemp Dolliver at Brookline Capital, suggesting a 5.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IBIO Analyst Consensus
IBIO Price Target Range
Latest IBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IBIO.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 17, 2024 | LUCID CAPITAL MARKETS | Dev Prasad | Buy | Initiates | $6.00 |
Jul 22, 2024 | Brookline Capital | Kemp Dolliver | Buy | Initiates | $3.60 |
Jun 3, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
May 28, 2024 | Chardan Capital | Keay Nakae | Buy | Initiates | $5.00 |
Feb 16, 2023 | JMP Securities | Roy Buchanan | Market Perform | Downgrade | $0.00 |
Oct 7, 2022 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $0.17 |
Nov 29, 2021 | JMP Securities | Roy Buchanan | Outperform | Initiates | $1.50 |
Jan 22, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
Jan 21, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
Jun 26, 2020 | Alliance Global Partners | Buy | Initiates | $0.00 |
Stocks Similar to iBio Inc
The following stocks are similar to iBio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
iBio Inc (IBIO) Financial Data
iBio Inc has a market capitalization of $33.87M with a P/E ratio of 2.6x. The company generates $375,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -2,209.5% and return on equity of -123.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

iBio Inc (IBIO) Company Overview
About iBio Inc
Develops AI antibody solutions for diseases.
The company operates as a preclinical stage biotechnology firm focusing on developing innovative antibody therapies using artificial intelligence. It generates revenue through partnerships and collaborations, such as its agreement with AstralBio for developing novel antibodies, while also working on proprietary products targeting cancer and cardiometabolic diseases.
iBio has a diverse pipeline of products including IBIO-101 and CCR8, aimed at enhancing immune responses and targeting cancer cells. Its advanced technology platforms, such as EngageTx and ShieldTx, position it to create conditionally activated antibodies that may improve treatment efficacy and safety. Founded in 2008, the company is based in San Diego, California.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Martin B. Brenner D.V.M., Ph.D.
Country
United States
IPO Year
2008
Website
ibioinc.comiBio Inc (IBIO) Latest News & Analysis
iBio, Inc. (NYSEA:IBIO) reported its Q2 financial results for the period ending Dec. 31, 2024, and provided a corporate update on its progress.
iBio's financial results and corporate updates can indicate its performance and growth potential, influencing stock valuation and investor sentiment.
iBio has launched a new program featuring a Myostatin + Activin A bispecific antibody aimed at promoting weight loss and preventing muscle loss, with potential for less frequent dosing than current treatments.
iBio's new bispecific antibody program could significantly impact obesity treatment, potentially increasing its market share and revenue, which may enhance investor confidence and stock performance.
Dosing for the advanced myostatin program is currently underway in a non-human primate study, indicating progress in research and development.
Progress in the advanced myostatin program suggests potential breakthroughs in muscle-related therapies, impacting future revenue and market positioning for the company.
iBio, Inc. (NYSEA:IBIO) reported its financial results for the fiscal year ending June 30, 2024, and shared a corporate update on September 20, 2024.
iBio's financial results and corporate update signal its performance and strategic direction, impacting stock valuation and investor sentiment regarding future growth potential.
iBio to Participate in Upcoming Investor Conferences
5 months agoiBio, Inc. (NYSEA:IBIO) announced that CEO Martin Brenner and CFO Felipe Duran will participate in upcoming investor conferences, highlighting the company's focus on precision antibody immunotherapies.
CEO and CFO participation in investor conferences signals potential growth and transparency, which could enhance investor confidence and affect stock performance for iBio, Inc.
iBio appoints a life sciences veteran to lead strategic alliances for its machine learning platform focused on antibody discovery and cardiometabolic targets.
Leadership change in iBioโs strategic alliances signals potential growth and innovation in antibody discovery, enhancing its competitive edge and market value in the life sciences sector.
Frequently Asked Questions About IBIO Stock
What is iBio Inc's (IBIO) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, iBio Inc (IBIO) has a median price target of $4.78. The highest price target is $5.96 and the lowest is $3.60.
Is IBIO stock a good investment in 2025?
According to current analyst ratings, IBIO has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for IBIO stock?
Wall Street analysts predict IBIO stock could reach $4.78 in the next 12 months. This represents a 39.4% increase from the current price of $3.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is iBio Inc's business model?
The company operates as a preclinical stage biotechnology firm focusing on developing innovative antibody therapies using artificial intelligence. It generates revenue through partnerships and collaborations, such as its agreement with AstralBio for developing novel antibodies, while also working on proprietary products targeting cancer and cardiometabolic diseases.
What is the highest forecasted price for IBIO iBio Inc?
The highest price target for IBIO is $5.96 from at , which represents a 73.8% increase from the current price of $3.43.
What is the lowest forecasted price for IBIO iBio Inc?
The lowest price target for IBIO is $3.60 from Kemp Dolliver at Brookline Capital, which represents a 5.0% increase from the current price of $3.43.
What is the overall IBIO consensus from analysts for iBio Inc?
The overall analyst consensus for IBIO is bullish. Out of 6 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.78.
How accurate are IBIO stock price projections?
Stock price projections, including those for iBio Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.